Mustang Bio Inc (MBIO)
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on cell therapy programs for hard-to-treat cancers and certain autoimmune diseases in the United States. Its pipeline includes MB-106, a CD20-directed CAR T-cell therapy being studied in Phase I for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune conditions; MB-109, a program combining MB-101 and MB-108 for IL13Ra2-positive relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, which completed Phase I evaluation in glioblastoma; and MB-108, a Phase I program related to herpes simplex virus-1 oncolytic virus C134. The company has licensing agreements with City of Hope National Medical Center and Nationwide Children’s Hospital. Mustang Bio was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MBIO
|
$1.01
|
65.9% Upside
|
Bargain
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 4, 2026
|
-1.8x
|
0.6x
|
—
|
4.94 M
|
-11.485 M
|
0.0%
|
70.6%
|
-72.0
|
—
|
179.3%
|
